(a) Immunoblot analysis of total IgG (50 kDa heavy chain) and ficolin levels in the pooled sera of mice (n=8) (top panel) and detection of nIgG (50 kDa heavy chain of mouse IgG3) and ficolin in nIgG:ficolin complexes (pulled down by Protein G beads) in serum (boxed in red), post-infection with 10 6 or 10 7 cfu P. aeruginosa over time course. (b) Immunoblot to detect nIgG (50 kDa heavy chain of IgG3) and ficolin (37 kDa; human and 35 kDa; mouse) in nIgG:ficolin complexes (pulled down by Protein G beads) in human serum and pooled mice sera (n=8) upon incubation with P. aeruginosa (P.a.) for 30 min at room temperature. Prior to incubation with the bacteria, the sera were incubated with increasing doses of nIgG peptides (non-binding or binding to ficolin) for 15 min at room temperature. Sera pre-incubated without or with the peptides (5:1 molar ratio to ficolin) but without P.a. incubation, served as controls. The samples were derived from the same experiment, resolved under 12% reducing SDS-PAGE and the gels and blots were processed in parallel. Representative immunoblots from three independent experiments is shown. Figure 3d . Coimmunoprecipitation assay to show the deposition of H-ficolin, nIgG and C1q on GlcNAc beads under normal and infection-inflammation conditions. The samples were derived from the same experiment, resolved under 12% reducing SDS-PAGE and the gels and blots were processed in parallel. Representative immunoblots from three independent experiments is shown.
SUPPLEMENTARY METHODS
Sera, proteins and antibodies. Uninfected human serum samples were obtained from healthy adult donors with informed consent, under Institutional Guidelines (IRB Ref.
Code: 08-296). The concentration of the sera was measured by NanoDrop™ ND-1000 Scientific, Wilmington spectrophotometer (Thermo Fisher Scientific) to ensure that equal amounts of proteins were used in each experiment. IgG was purified from the human and mouse uninfected serum using Protein G affinity chromatography. Serum was depleted of IgG by incubating overnight at 4˚C with Protein G beads. Serum was depleted of ficolin by incubating overnight at 4˚C with antificolin pre-bound to Protein G beads. The FBG domain of L-, H-and M-ficolins were recombinantly expressed and purified from HEK293T cells. Anti-H-ficolin (AF2367) and anti-goat secondary NL557-conjugated (NL001) antibodies were from R&D Systems (Minneapolis). Anti-mouse ficolin (648102) was from Biolegend. Anti-mouse IgG (Fc specific; M2650) was from Sigma. Anti-human IgG3 (053600) and anti-mouse IgG3 (406802) that detect the respective heavy chain, were from Invitrogen and Biolegend, respectively. Secondary anti-goat, anti-rabbit and anti-mouse antibodies with HRP-conjugation were from Dako A/S (Denmark). Polyclonal anti-human C1q (ab14004) and purified human C1q (ab96363) were from Abcam. Secondary antibodies conjugated with Alexa-488 and Alexa-594 were purchased from Invitrogen (Carlsbad). GlcNAc-Sepharose beads were from Pierce (Rockford).
Bacterial strain. The lab-adapted Pseudomonas aeruginosa strain, PAO1, used in this study was kindly provided by Professor B. H. Iglewski (University of Rochester, Rochester, USA).
Purification of nIgG from uninfected human serum. "nIgG" is defined as the whole repertoire of IgG in the serum of uninfected animals and human individuals, previously not exposed to a particular antigen 1 . We therefore purified nIgG from human and mice uninfected serum using Vivaspin pre-packed Protein G spin column (Sartorius), according to the manufacturer's instructions. SDS-PAGE (12% resolving gel) under reducing conditions and mass spectrometry were used to check the purity and confirm the identity of nIgG.
Isolation of representative nIgG (anti-alpha gal IgG) from purified human IgG. The agarose beads immobilized with streptavidin (Thermo Scientific) were loaded onto the column (Sartorius) and equilibrated with 5 column volumes of binding buffer (PBS containing 0.1 M phosphate, 0.15 M NaCl, pH 7.2 and 1% NP-40). The biotinylated gal-alpha1-3 gal (alpha-gal) (Dextra Labs, UK) was added to the column (3 mg alpha-gal /ml of immobilized streptavidin beads) and incubated for 30 min at room temperature. The column was then washed with 10 volumes of binding buffer. Purified IgG was added to the column and incubated overnight at 4˚C. After washing the column with 10 volumes of binding buffer, the bound anti-alpha gal IgG was eluted with 5 column volumes of elution buffer (0.1 M glycineHCl, pH 2.7), into tubes containing neutralization buffer (1 M Tris, pH 8.0), whose volume was equal to 1/10 the volume of the eluted fraction. The buffer was exchanged to PBS using centrifugal filter devices with a 3-kDa molecular weight cut-off (Amicon Ultra, Millipore). SDS-PAGE (12% resolving gel) under reducing conditions and Western blotting were used to check the purity and confirm the identity of purified anti-alpha gal IgG.
Purification of H-ficolin from uninfected human serum. The proteins in uninfected human serum were precipitated using 4-8% PEG 6000 and dissolved in 50 mM Tris, pH 7.4, 145 mM NaCl, 0.05% (v/v) Tween-20 (TBST). The mixture of proteins was then chromatographed through an 8-ml human serum albumin (HSA)-conjugated Sepharose 4B column. The eluate was then passed through an 8-ml column containing acetylated-HSA-Sepharose 4B beads. The column was sequentially washed with TBST followed by TBST containing 200 mM GlcNAc. H-ficolin bound to the column was eluted in two steps using 1 M Na-acetate, 0.05% Tween 20, 10 mM CaCl 2 , pH 7.5 followed by 10 mM diethylamine, 0.05% Tween 20, 10 mM CaCl 2 , pH 11.5. Eluate from the second step was neutralized with 10 mM Tris-HCl, pH 7.4. The eluted proteins were then concentrated through a 1-ml MonoQ column (GE healthcare). The buffer was exchanged to 50 mM Tris, pH 7.4, 145 mM NaCl (TBS) using centrifugal filter devices with a 3-kDa molecular weight cut-off (Amicon Ultra, Millipore). Western blotting and mass spectrometry were used to check the purity and confirm the identity of Hficolin.
Expression and purification of recombinant ficolin FBG domains. cDNA fragments of the FBG domains of L-, H-and M-ficolins were cloned into the pSectag 2B vector (Invitrogen) and transfected into HEK293T by lipofectamine 2000 (Invitrogen). Purification was carried out as described previously 2 . The purity of the recombinant proteins was analyzed by reducing conditions of SDS PAGE (12% resolving gel).
SDS-PAGE and Western blot.
Protein samples were derived from the same experiment and the PAGE gels and blots were processed in parallel. Equal amounts of serum proteins, purified proteins (IgG, ficolin or IgG:ficolin complex) or eluted samples from Protein G bead pulldown assays were boiled at 95 o C for 5 min and electrophoresed on 12% SDS-PAGE under reducing conditions, and transferred to PVDF (BioRad) membrane for 1 h at 70 V. The membrane was blocked for 2 h with 5% (w/v) skimmed milk in 50 mM Tris, pH 7.4, 145 mM NaCl, 0.05% (v/v) Tween-20 (TBST). The membrane was first probed with the primary antibody (overnight at 4C), washed four times with TBST, probed with the corresponding secondary antibody in the recommended titer for 1 h, and washed four times in TBST. The immunosignals were detected using Supersignal West Pico Chemiluminescent Substrate (Pierce) and exposed to X-ray film (Fujifilm, Japan).
Mass spectrometry (MS).
The protein bands of interest separated on the PAGE gel were excised and in-gel digested with trypsin (Promega) as previously described 3 . The trypsinized peptide samples were analysed by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) with Voyager-DE STR Biospectrometry Workstation (Applied Systems) in the Proteins and Proteomics Centre, National University of Singapore. The peptide mass and sequences were analysed using Matrix Sciences Mascot search at http://www.matrixscience.com/search_form_select.html. ELISA for measurement of protein:protein binding. ELISA was performed as described previously 2 , to test the interaction between nIgG and ficolin FBG domains. Briefly, 1 µg of GlcNAc-BSA was immobilized in each well of a 96-well Maxisorp™ plate (NUNC, Denmark), followed by incubation with 0.8 µg of ficolin FBG, at 37 ˚C for 2h. Then, increasing doses of purified IgG (from uninfected human serum) diluted in buffers were added and incubated at 37 ˚C for 2 h. After washing the wells repeatedly to remove unbound proteins, bound nIgG was detected with the primary anti-human IgG3 (1:3000) followed by corresponding HRP-conjugated secondary antibody (1:3000). After adding ABTS substrate (Roche Diagnostics, Germany), the OD 405 nm was read. Wells incubated with HSA on immobilized ficolin served as negative controls, unless otherwise stated.
Computational modeling. The crystal structures of human IgG-Fc (PDB entry code: 1H3Y), H-ficolin FBG (ligand-free; PDB entry code: 2J64) and C1q (PDB entry code: 2JG8) were used for in silico modeling studies. The models were subjected to energy minimization in Discovery Studio 2.5 (Accelrys Inc.) and used as the template in the following simulations. To generate the docking model for IgG-Fc:H-ficolin FBG and C1q:IgG Fc, the ZDOCK program in Discovery Studio 2.5 program package was used. A total of 54,000 docked poses were generated. The top 100 poses were categorized into different clusters, and the top poses which fitted with our experimental data were selected for further analysis.
